Clinical Research Directory
Browse clinical research sites, groups, and studies.
Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in BRCA-associated Triple-negative Locally Advanced Breast Cancer
Sponsor: N.N. Petrov National Medical Research Center of Oncology
Summary
This study was designed to evaluate the safety and efficacy of neoadjuvant therapy with mitomycin and carboplatin in patients with BRCA-associated locally advanced triple-negative breast cancer.
Official title: Use of a Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in Patients With BRCA-associated Triple-negative Locally Advanced Breast Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2022-09-27
Completion Date
2030-12-01
Last Updated
2026-09-15
Healthy Volunteers
No
Interventions
Neoadjuvant Chemotherapy (NACT)
neoadjuvant chemotherapy according to the regimen of mitomycin in combination with carboplatin, followed by paclitaxel
Neoadjuvant Chemotherapy (NACT)
neoadjuvant chemotherapy according to the AC regimen, followed by paclitaxel in combination with carboplatin
Locations (1)
N.N. Petrov National Medical Research Center of Oncology
Saint Petersburg, Russia